Erbitux Opportunity In Japan Has Been Overlooked By Investors
This article was originally published in PharmAsia News
Executive Summary
ImClone said July 16 that its oncologic Erbitux (cetuximab) has been approved in Japan for treatment of advanced colon cancer. Under an existing deal, Merck KGaA will receive 50 percent of profits from sales in Japan, and ImClone and Bristol-Myers Squibb will receive 25 percent each. An application for Erbitux in earlier-stage colon cancer is pending with Japanese regulators. Several analysts say that the Japanese market is an opportunity for Erbitux that has been overlooked by investors. (Click here for more
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.